What are the recommended dosing regimens for budesonide (inhaled, nasal, oral, and rectal) for asthma, chronic obstructive pulmonary disease, allergic rhinitis, Crohn’s disease, and ulcerative colitis?

Budesonide Dosing Regimens Across Indications

Asthma

Inhaled Budesonide for Pediatric Asthma (Ages 12 months to 8 years)

For children with mild to moderate persistent asthma not previously on inhaled corticosteroids, start with budesonide inhalation suspension 0.25 mg once daily or 0.5 mg once daily via nebulizer. 1

• Low-dose therapy: 0.25-0.5 mg daily (can be given once daily or divided twice daily) 1
• Medium-dose therapy: Up to 1.0 mg daily 2
• For children previously maintained on inhaled corticosteroids, use 0.25 mg twice daily or 0.5 mg twice daily 1
• Maximum benefit typically achieved after 4-6 weeks, though symptom improvement may begin within 2-8 days 1

Inhaled Budesonide for Adults with Asthma

Adults with persistent asthma should receive budesonide via metered-dose inhaler at doses ranging from 176 mcg daily (low-dose) to >352 mcg daily (high-dose). 2

• The FACET study demonstrated that budesonide 200-800 mcg daily combined with formoterol reduced both mild and severe exacerbations by 40% and 29%, respectively 3
• Long-acting beta-agonists should always be combined with inhaled corticosteroids, never used as monotherapy 3

Intermittent Budesonide for Young Children with Recurrent Wheezing

For children aged 0-4 years with recurrent wheezing triggered by respiratory infections, administer budesonide inhalation suspension 1 mg twice daily for 7 days at the first sign of respiratory tract infection. 3

• This regimen reduces exacerbations requiring systemic corticosteroids 3
• Caregivers can initiate treatment at home with clear written instructions 3
• Monitor growth carefully, as data on growth effects are conflicting 3

---

Allergic Rhinitis

For seasonal and perennial allergic rhinitis in adults and children, budesonide aqueous nasal spray 64 mcg once daily (one 32-mcg spray per nostril) is the recommended starting dose. 4

• This low-volume, once-daily formulation is effective for moderate to severe persistent allergic rhinitis 4
• Well tolerated with adverse-event profile similar to placebo 4
• No clinically meaningful HPA axis suppression at doses up to 4-fold higher than the recommended starting dose 4

---

Crohn's Disease

Mild to Moderate Ileocecal Crohn's Disease

Budesonide 9 mg once daily for exactly 8 weeks is the first-line therapy for mild to moderate ileocecal Crohn's disease (CDAI <300). 3, 5

• Achieves remission in approximately 51% of patients versus 20% with placebo 5
• Taper over 1-2 weeks after achieving remission at week 8, rather than stopping abruptly 3, 5
• Assess symptomatic response between weeks 4-8; if no improvement by week 4, escalate to systemic corticosteroids 5
• Do not use budesonide for maintenance therapy beyond the initial 8-week induction plus taper—it is ineffective for maintaining remission and increases risk of adrenal suppression and bone loss 3, 5

Disease Location Considerations

• Budesonide is effective only for disease confined to the ileum and/or ascending colon (proximal colon) 3, 5
• No evidence of benefit for distal colonic inflammation 3, 5
• In severe Crohn's disease (CDAI >300), budesonide is inferior to prednisolone and should not be used 3, 5

Colonic Crohn's Disease

For active Crohn's colitis, use systemic corticosteroids such as prednisolone 40 mg daily, tapering by 5 mg weekly. 3

• Ileal-release budesonide has no proven benefit for distal colonic inflammation 3
• No trials exist for colonic-release budesonide MMX in Crohn's disease 3

---

Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

For patients with mild to moderate ulcerative colitis who fail or are intolerant to 5-ASA therapy, budesonide MMX 9 mg once daily for up to 8 weeks is recommended. 3, 6

• The AGA suggests using standard-dose oral mesalamine or diazo-bonded 5-ASA rather than budesonide MMX for initial induction of remission 3
• Budesonide MMX should be reserved for patients refractory to optimized oral and rectal 5-ASA 3
• Subgroup analysis shows highest efficacy in patients with left-sided disease, not extensive colitis 3

Alternative: Beclomethasone Dipropionate

• Beclomethasone dipropionate 5 mg is non-inferior to prednisone and more effective than placebo for mild to moderate ulcerative colitis 3
• Can be used as an alternative when budesonide MMX is not accessible due to cost or regional restrictions 3

Administration Instructions

• Swallow budesonide extended-release tablets whole; do not chew, crush, or break 6
• Can be taken with or without food 6

---

COPD

For acute exacerbation of COPD (AECOPD), nebulized budesonide 8 mg/day (given as 4 mg twice daily) improves pulmonary function and symptoms more effectively than the conventional 4 mg/day dose. 7

• High-dose nebulized budesonide (8 mg/day) showed faster improvement in FEV1%, CAT scores, and spirometry compared to 4 mg/day 7
• For maintenance therapy in stable COPD, budesonide/formoterol 320/9 mcg twice daily maintains lung function, prolongs time to first exacerbation (254 vs 96 days with placebo), and reduces exacerbation frequency (1.38 vs 1.80 per patient-year) 8

---

Important Safety Considerations and Monitoring

Drug Interactions

Avoid concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir) or grapefruit juice, as these significantly increase systemic budesonide concentrations and risk of Cushing syndrome. 2, 6

• If CYP3A4 inhibitors are necessary, monitor closely for hypercorticism and consider discontinuing budesonide or the inhibitor 6

Systemic Effects

• Monitor for signs of hypercorticism and adrenal axis suppression during treatment 6
• Patients with moderate to severe liver disease require closer monitoring for hypercorticism 6
• Prolonged use (>6-12 months) predisposes to bone loss; consider osteoporosis screening and prevention in patients requiring long-term therapy 9, 2

Immunosuppression

• Budesonide suppresses the immune system and increases infection risk with any pathogen 6
• Can reduce resistance to new infections, exacerbate existing infections, and mask signs of infection 6
• Risk of infectious complications increases with increasing corticosteroid dosages 6

Local Side Effects (Inhaled/Nasal)

• Oral candidiasis, dysphonia, throat irritation (inhaled) 2, 10
• Nasal stinging, dry nose, slight nasal bleeding (intranasal) 4, 10
• Face washing after inhalation reduces local adverse effects 2

Transitioning from Systemic Corticosteroids

• When transferring from systemic corticosteroids to budesonide, taper the systemic steroid cautiously and monitor adrenocortical function 6
• Symptoms of acute adrenal suppression or benign intracranial hypertension may develop during transition 6
• Previously controlled allergies (rhinitis, eczema) may unmask during transition 6

Stress Situations

• In patients undergoing surgery or other stress, supplementation with systemic glucocorticosteroids is recommended, as budesonide can reduce HPA axis response to stress 6